{"commentary":{"count":14,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":5,"x_thread":5,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05079230\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ENHANCE-3","nct_id":"NCT05079230","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=enhance-3-nct05079230. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ENHANCE-3","arms":[{"description":"Participants will receive\n\n* magrolimab: 1 mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and then every week for 5 doses and every 2 weeks thereafter\n* venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter\n* azacitidine: 75 mg/m\\^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle\n\nEach cycle is 28 days.","label":"Magrolimab + Venetoclax + Azacitidine","type":"EXPERIMENTAL"},{"description":"Participants will receive\n\n* magrolimab matching placebo: Days 1, 4, 8, 11, and 15, then every week for 5 doses and every 2 weeks thereafter\n* venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter\n* azacitidine: 75 mg/m\\^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle\n\nEach cycle is 28 days.","label":"Magrolimab Matching Placebo + Venetoclax + Azacitidine","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-04-11","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia"],"enrollment":{"count":378,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Magrolimab","type":"DRUG"},{"name":"Venetoclax","type":"DRUG"},{"name":"Azacitidine","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2025-04-04","lead_sponsor":"Gilead Sciences","official_title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-04-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to 1.6 years"}],"references":[{"citation":"Daver N, Vyas P, Huls G, Dohner H, Maury S, Novak J, Papayannidis C, Martinez Chamorro C, Montesinos P, Niroula R, Fenaux P, Esteve J, Wu SJ, De Voeght A, Mayer J, Valk PJM, Johnson L, Dong M, Liu K, Kuwahara S, Caldwell K, Guru Murthy GS. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood. 2025 Jul 31;146(5):601-611. doi: 10.1182/blood.2024027506.","pmid":"40233321","type":"DERIVED"},{"citation":"Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 Nov 1;41(31):4893-4904. doi: 10.1200/JCO.22.02604. Epub 2023 Sep 13.","pmid":"37703506","type":"DERIVED"}],"start_date":{"date":"2022-07-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","url":"https://clinicaltrials.gov/study/NCT05079230"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/enhance-3-nct05079230"}